These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 15736292

  • 1. Telmisartan vs. enalapril in type 2 diabetes.
    Parving HH, Hovind P, Rossing P.
    N Engl J Med; 2005 Feb 24; 352(8):835-6; author reply 835-6. PubMed ID: 15736292
    [No Abstract] [Full Text] [Related]

  • 2. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun 29; 148(26):51. PubMed ID: 16875382
    [No Abstract] [Full Text] [Related]

  • 3. Telmisartan vs. enalapril in type 2 diabetes.
    Loewenstein JE.
    N Engl J Med; 2005 Feb 24; 352(8):835-6; author reply 835-6. PubMed ID: 15736291
    [No Abstract] [Full Text] [Related]

  • 4. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 5. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
    Zidek W.
    MMW Fortschr Med; 2004 Oct 14; 146(42):51-2. PubMed ID: 15536706
    [No Abstract] [Full Text] [Related]

  • 6. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
    Nitschmann S, Girndt M, Köhler H.
    Internist (Berl); 2005 Aug 14; 46(8):923-4, 926. PubMed ID: 15990988
    [No Abstract] [Full Text] [Related]

  • 7. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
    Barnett AH.
    Acta Diabetol; 2005 Apr 14; 42 Suppl 1():S42-9. PubMed ID: 15868119
    [Abstract] [Full Text] [Related]

  • 8. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 14; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 9. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
    Barnett A.
    J Am Soc Nephrol; 2006 Apr 14; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
    Rippin J, Bain SC, Barnett AH, DETAIL study.
    J Diabetes Complications; 2002 Apr 14; 16(3):195-200. PubMed ID: 12015188
    [Abstract] [Full Text] [Related]

  • 11. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects.
    Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H.
    Diabetes Care; 2005 Feb 14; 28(2):498. PubMed ID: 15677828
    [No Abstract] [Full Text] [Related]

  • 12. Telmisartan vs. enalapril in type 2 diabetes.
    Asgari AA, Sarvghadi F, Zahed N.
    N Engl J Med; 2005 Feb 24; 352(8):835-6; author reply 835-6. PubMed ID: 15728820
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension.
    Hannedouche T, Chanard J, Baumelou B, French Collaborative Telmisartan Study Group.
    J Renin Angiotensin Aldosterone Syst; 2001 Dec 24; 2(4):246-54. PubMed ID: 11881131
    [Abstract] [Full Text] [Related]

  • 14. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan 24; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb 24; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 16. [Effect of telmisartan on the psychological state and quality of life in stable hypertension patients].
    Andreeva GF, Gorbunov VM, Aĭvazian TA, Isaĭkina OIu, Voronina VP, Lerman OV.
    Eksp Klin Farmakol; 2004 Feb 24; 67(6):36-40. PubMed ID: 15707013
    [Abstract] [Full Text] [Related]

  • 17. Renin-Angiotensin system blockade for diabetic nephropathy prevention.
    Naviglio S, Pirozzi F.
    Am J Cardiol; 2010 May 15; 105(10):1505. PubMed ID: 20451706
    [No Abstract] [Full Text] [Related]

  • 18. [Arterial hypertension and type 2 diabetes mellitus: clinical evaluation of hemodynamic characteristics, possibility of correction].
    Tatarchenko IP, Pozdniakova NV, Mordovina AG, Sekerko SA, Morozova OI.
    Klin Med (Mosk); 2009 May 15; 87(10):20-4. PubMed ID: 20017345
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV, Dass EE.
    Indian J Pharmacol; 2015 May 15; 47(2):148-52. PubMed ID: 25878372
    [Abstract] [Full Text] [Related]

  • 20. Hypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure.
    Piccoli GB, Anania P, Biancone L, Mezza E, Vischi M, Jeantet A, Rabbia C, Savio D, Rossatto D, Gai M, Perin PC, Segoloni GP.
    Nephrol Dial Transplant; 2001 May 15; 16(5):1084-5. PubMed ID: 11328932
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.